ArticleSmall methods2025
Amphiphile-Assisted Synthesis of Ruthenium Nanoparticles for Controlled Release and Enhanced Antibacterial Activity.
Article in Small methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
A novel procedure for preparing Ruthenium nanoparticles (RuNPs) based on low-molecular-weight amphiphilic molecules and Ru(III) complexes as antibacterial agents with controlled release properties has been developed. Two hydrophobic Ru(III) complexes, Ru-TOA and Ru-Benza, analogs to the NAMI-A prodrug, are encapsulated within the core of the micelles formed through the self-assembly of these amphiphiles. The self-assembly of amphiphile I, which contains a double polar head, results in highly water-stable and monodispersed RuNPs incorporating both hydrophobic Ru complexes. These RuNPs exhibit hydrodynamic sizes ranging from 26.7 to 104.2 nm for NPs derived from Ru-TOA complex, and ≈10 nm for those derived from Ru-Benza. Compared to Ru(III) complexes, these RuNPs offer several advantages, including protection from aqueous degradation and enhanced bacterial uptake. Moreover, post-synthesis modification of the RuNPs with molecular staples based on polyethylene glycol chains of varying lengths enables controlled Ru release, reducing the burst effect. Interestingly, these RuNPs demonstrate excellent antibacterial activity, with minimum inhibitory concentration (MIC) values of 16 mg·L
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.